HARRIGAN EDMUND 4

4 · ACADIA PHARMACEUTICALS INC · Filed Jun 1, 2026

AI-generated summary of this filing

Updated Jun 1, 2026

ACADIA (ACAD) Director Edmund Harrigan Exercises Options, Receives Awards

What Happened

Director Edmund Harrigan reported exercising option(s) and receiving restricted stock units (RSUs) on May 29, 2026. The filing shows: exercise/conversion of 8,107 option-derived shares and grants/awards of 16,004 and 9,311 restricted stock units (totaling 33,422 shares/units). An equal number of 8,107 shares from the exercise were reported as disposed at $0 (derivative), while the RSUs and the exercise show $0 per-share in the filing (typical for award reporting).
This activity is not an open-market purchase or sale for cash; it represents option exercise and issuance/vesting of stock units (acquisitions), with a portion of exercised shares surrendered/treated at $0 in the report (commonly used to satisfy withholding or exercise settlement obligations).

Key Details

Transaction date: May 29, 2026; Form 4 filed June 1, 2026 (timely — within the two-business-day filing requirement).
Reported transactions: exercised/conversion of 8,107 shares (code M); 8,107 shares also reported disposed at $0 (derivative). Grants/awards (code A) of 16,004 and 9,311 restricted stock units (RSUs).
Prices/values reported: $0.00 per share for awards and the disposed portion; exercise acquired shares listed as N/A for price in filing.
Shares owned after the transaction: not specified in the information provided in this Form 4.
Footnotes: F1-F4 explain that RSUs represent contingent rights to receive one share each; some RSUs vested in full on May 29, 2026 (F2). Option and RSU vesting schedules are described (quarterly vesting over one year for options per F3; some RSUs vest earlier of one year or next annual meeting per F4).

Context

For retail investors: this filing reflects insider equity compensation events (option exercise and RSU awards/vestings), not an open-market buy or sale for cash. The reported disposal of 8,107 shares at $0 likely reflects shares surrendered/used in settlement (e.g., tax withholding or exercise cost), a common administrative step that does not necessarily indicate a market sale.
These types of filings are routine for directors receiving and settling equity-based compensation; they do not by themselves signal a change in the director’s view of the company.

Form 4

Period: 2026-05-29

Director

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-05-29+8,107→ 43,148 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-05-29−8,107→ 0 total
→ Common Stock (8,107 underlying)
Award
Director Stock Options (Right to Buy)
[F3]
2026-05-29+16,004→ 16,004 total
Exercise: $21.66Exp: 2036-05-28→ Common Stock (16,004 underlying)
Award
Restricted Stock Units
[F1][F4]
2026-05-29+9,311→ 9,311 total
→ Common Stock (9,311 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
[F2]The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
[F3]The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
[F4]The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.

Signature

/s/ Jennifer J. Rhodes, Attorney-in-Fact|2026-06-01

1 file